In experimental systems, interference with coagulation can affect tumor biology. Tumor-mediated activation of the hemostatic system has been implicated in both the formation of tumor stroma and the promotion of hematogenous metastasis. We emphasize that hypercoagulation is a frequent symptom in metastatic renal cell carcinoma (MRCC) patients and clinically correlates with progression of the disease. It has been suggested that hypercoagulation is a possible negative predictor for a response to immunotherapy in MRCC patients
